Even though the incidence of KRAS amplification compared to its mutation is low, such as less than10% of patients with gastric cancer or CRC and 17% in EAC, clinical features of patients with KRAS amplification are distinct, and the amplification is usually associated with poor prognosis in these patients41–44. Here, KRAS is linked to colorectal carcinoma.